



Rabies Work Group Update

Sharon Frey, MD, FACP, FIDSA

Chair, ACIP Rabies Work Group

ACIP Meeting

February 24, 2021

Work Group Members

ACIP Members

Sharon Frey (chair)

Lynn Bahta

Liaison Representatives

AAFP- James Stevermer

NASPHV- Katie Brown and Sally Slavinski

NACCHO- Matt Zahn

AAP- Elizabeth Bennett

APhA- Karl Hess

NACI- Julie Emili and Linlu Zhao

FDA- Paula Agger and Robin Levis

NIH- Eun-Chung Park

Invited Consultants

Subject Matter Expert- Deborah Briggs

Subject Matter Expert- Susan Moore

Travel medicine- David Shlim

Emergency Medicine – Greg Moran

APHL-Michael Pentella

CDC

Rabies Work Group leads – Agam Rao

& Jesse Blanton

Immunization Safety Office – Pedro Moro

Division of Global Migration and

Quarantine- Kristina Angelo

ACIP rabies sessions until now: PreP

- **October 2018:** Introduced formation of WG
- **October 2019 and February 2020**
 - Reviewed vaccine safety, and work group considerations for changes to PrEP
 - Gathered feedback from committee about data they would need to make changes to 2008 ACIP recommendations
 - Conveyed WG conclusions about pediatric patients having similar responses (if not more robust) than those of healthy persons
 - Showed evidence to support WG move to use data from intradermal series to influence intramuscular series recommendations
 - Explained why 0.5 IU/mL should be the minimum rabies antibody titer cut-off
 - Redefined risk categories for PrEP
 - Presented GRADE and EtR for 2 PrEP policy questions


WG activities since last ACIP meeting

- **Understanding pre-exposure prophylaxis (PrEP) costs, including those incurred by PrEP recipients**
- **Post-exposure prophylaxis (PEP)**
 - Developing guidance for front line clinicians who make decisions about whether PEP is indicated
 - Evaluating two Rabies Immune Globulin (RIG) products licensed since 2008 ACIP recommendations
 - Assessing data about the current ACIP recommendation for RIG infiltration around a wound and for remainder administered intramuscularly
 - Evaluating immunogenicity of PEP in persons aged ≥ 65

WG's goal for today

- PrEP
 - Address questions raised by the ACIP about PrEP costs
 - Summarize clinical guidance presented at previous meetings
 - Recap policy questions, Evidence tables, and Evidence to Recommend frameworks
 - Commence vote on two proposed policy questions
- PEP
 - Provide background information about PEP
 - Convey WG conclusions about RIG

Anticipated timeline



Today's agenda

- Rabies pre-exposure prophylaxis: Summary of background information important to today's vote
- Rabies pre-exposure prophylaxis: Summary of GRADE and EtR

- Rabies post-exposure prophylaxis: Background
- Work group interpretations of data about rabies immune globulin
- Next steps

===== Break and public comment

- PrEP vote (two recommendations)

All presentations are provided by Dr. Agam Rao (CDC/NCEZID)

Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

